What is SPID® technology?
A patented 3D screen-printing process for producing pharmaceutical dosages with a defined multi-layer structure. Enables flexible release profiles, high throughput rates (up to 1.5 million units/day), and QR code integration.
What stage of development is the company in?
Laxxon is conducting pilot PK studies, for example, on GLP-1 (LXM.2) and Levodopa/Carbidopa (LXM.5), with significantly increased bioavailability. Published results show up to 10-fold improvements compared to existing formulations.
What does the IP portfolio look like?
The company owns over 230 patents/applications with more than 5,500 claims. Latest success: US patent for sequential drug release in multi-drug systems.
Who are the partners and how is production carried out?
Cooperation with Adare Pharma Solutions for cGMP production in Europe (Italy) USA. External internal incubator for partner projects (4+) and in-house patents (13+ generic assets).
Receive exclusive updates on exciting commodity companies, market analyses, and investment opportunities directly in your inbox.
By submitting the form, you agree that your contact details will be processed for sending the newsletter.
Stay up to date: Our GOLDINVEST newsletter regularly informs you about current company news, market analyses, and exciting investment opportunities from the world of commodities.
Track the current price developments of key commodities such as gold, silver, copper, and lithium – including charts, market commentaries, and historical trends.
Here you will find in-depth background knowledge on commodities, markets, and exploration companies – concisely explained and easy to understand for beginners and professionals.
Our glossary explains key terms from the world of commodities, stock exchange, and exploration – ideal for quick reference and better understanding of our articles.
The leading platform for commodity news, market analyses, and company reports in the German-speaking region.
Copyright © 2025. GOLDINVEST Consulting GmbH. All rights reserved.
